Of note, although mutation-based neoantigens are an attractive model for therapeutic vaccines, clonal loss of the IDH-mutant allele has also been noted in recurrent glioma [53], thereby a potential mechanism of resistance. The gene discussed is IDH2; the disease is central nervous system cancer.